The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization

Marian D. Damewood, John S. Hesla, William D. Schlaff, Meriella Hubbard, John Repke, John A. Rock

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prior to initiating routine fetal cord serum (FCS) supplementation in our in vitro laboratory, the incidence of HIV in 306 random fetal cord samples obtained at the Labor and Delivery Unit of the Johns Hopkins Hospital from July 1985 to January 1988 was determined from a crosssectional patient sample. Of 306 samples, 3 (0.98%) were positive for HIV, and confirmed by Western blot analysis, enzyme immunoassay (ELISA), a prevalence significantly higher than a national sample (0.012%). The use of FCS in this setting was determined to be an unacceptable risk to patients undergoing in vitro fertilization. The 90-day quarantine period for verification of HIV seronegativity applied to semen donors may not be applicable to FCS sampling. Patient risk may also increase with pooling of FCS samples prior to HIV testing.

Original languageEnglish (US)
Pages (from-to)365-366
Number of pages2
JournalJournal of in Vitro Fertilization and Embryo Transfer
Volume7
Issue number6
DOIs
StatePublished - Dec 1 1990

Fingerprint

Fertilization in Vitro
HIV
Incidence
Serum
Quarantine
Immunoenzyme Techniques
Western Blotting
Enzyme-Linked Immunosorbent Assay
Tissue Donors

All Science Journal Classification (ASJC) codes

  • Embryology
  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Developmental Biology

Cite this

Damewood, Marian D. ; Hesla, John S. ; Schlaff, William D. ; Hubbard, Meriella ; Repke, John ; Rock, John A. / The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization. In: Journal of in Vitro Fertilization and Embryo Transfer. 1990 ; Vol. 7, No. 6. pp. 365-366.
@article{eb323ab47bc24452b8b8509514c4b803,
title = "The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization",
abstract = "Prior to initiating routine fetal cord serum (FCS) supplementation in our in vitro laboratory, the incidence of HIV in 306 random fetal cord samples obtained at the Labor and Delivery Unit of the Johns Hopkins Hospital from July 1985 to January 1988 was determined from a crosssectional patient sample. Of 306 samples, 3 (0.98{\%}) were positive for HIV, and confirmed by Western blot analysis, enzyme immunoassay (ELISA), a prevalence significantly higher than a national sample (0.012{\%}). The use of FCS in this setting was determined to be an unacceptable risk to patients undergoing in vitro fertilization. The 90-day quarantine period for verification of HIV seronegativity applied to semen donors may not be applicable to FCS sampling. Patient risk may also increase with pooling of FCS samples prior to HIV testing.",
author = "Damewood, {Marian D.} and Hesla, {John S.} and Schlaff, {William D.} and Meriella Hubbard and John Repke and Rock, {John A.}",
year = "1990",
month = "12",
day = "1",
doi = "10.1007/BF01130593",
language = "English (US)",
volume = "7",
pages = "365--366",
journal = "Journal of Assisted Reproduction and Genetics",
issn = "1058-0468",
publisher = "Springer New York",
number = "6",

}

The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization. / Damewood, Marian D.; Hesla, John S.; Schlaff, William D.; Hubbard, Meriella; Repke, John; Rock, John A.

In: Journal of in Vitro Fertilization and Embryo Transfer, Vol. 7, No. 6, 01.12.1990, p. 365-366.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The incidence of human immunodeficiency virus (HIV) in fetal cord samples utilized as serum supplements for in vitro fertilization

AU - Damewood, Marian D.

AU - Hesla, John S.

AU - Schlaff, William D.

AU - Hubbard, Meriella

AU - Repke, John

AU - Rock, John A.

PY - 1990/12/1

Y1 - 1990/12/1

N2 - Prior to initiating routine fetal cord serum (FCS) supplementation in our in vitro laboratory, the incidence of HIV in 306 random fetal cord samples obtained at the Labor and Delivery Unit of the Johns Hopkins Hospital from July 1985 to January 1988 was determined from a crosssectional patient sample. Of 306 samples, 3 (0.98%) were positive for HIV, and confirmed by Western blot analysis, enzyme immunoassay (ELISA), a prevalence significantly higher than a national sample (0.012%). The use of FCS in this setting was determined to be an unacceptable risk to patients undergoing in vitro fertilization. The 90-day quarantine period for verification of HIV seronegativity applied to semen donors may not be applicable to FCS sampling. Patient risk may also increase with pooling of FCS samples prior to HIV testing.

AB - Prior to initiating routine fetal cord serum (FCS) supplementation in our in vitro laboratory, the incidence of HIV in 306 random fetal cord samples obtained at the Labor and Delivery Unit of the Johns Hopkins Hospital from July 1985 to January 1988 was determined from a crosssectional patient sample. Of 306 samples, 3 (0.98%) were positive for HIV, and confirmed by Western blot analysis, enzyme immunoassay (ELISA), a prevalence significantly higher than a national sample (0.012%). The use of FCS in this setting was determined to be an unacceptable risk to patients undergoing in vitro fertilization. The 90-day quarantine period for verification of HIV seronegativity applied to semen donors may not be applicable to FCS sampling. Patient risk may also increase with pooling of FCS samples prior to HIV testing.

UR - http://www.scopus.com/inward/record.url?scp=0025597994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025597994&partnerID=8YFLogxK

U2 - 10.1007/BF01130593

DO - 10.1007/BF01130593

M3 - Article

VL - 7

SP - 365

EP - 366

JO - Journal of Assisted Reproduction and Genetics

JF - Journal of Assisted Reproduction and Genetics

SN - 1058-0468

IS - 6

ER -